%0 Journal Article
%A Piñana, Jose Luis
%A Lopez-Corral, Lucia
%A Martino, Rodrigo
%A Montoro, Juan
%A Vazquez, Lourdes
%A Perez, Ariadna
%A Martin-Martin, Gabriel
%A Facal-Malvar, Ana
%A Ferrer, Elena
%A Pascual, María-Jesus
%A Sanz-Linares, Gabriela
%A Gago, Beatriz
%A Sanchez-Salinas, Andres
%A Villalon, Lucia
%A Conesa-Garcia, Venancio
%A Olave, Maria T
%A Lopez-Jimenez, Javier
%A Marcos-Corrales, Sara
%A Garcia-Blazquez, Marta
%A Garcia-Gutierrez, Valentin
%A Hernandez-Rivas, Jose Angel
%A Saus, Ana
%A Espigado, Ildefonso
%A Alonso, Carmen
%A Hernani, Rafael
%A Solano, Carlos
%A Ferrer-Lores, Blanca
%A Guerreiro, Manuel
%A Ruiz-Garcia, Montserrat
%A Muñoz-Bellido, Juan Luis
%A Navarro, David
%A Cedillo, Angel
%A Sureda, Anna
%T SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
%D 2021
%U http://hdl.handle.net/10668/19952
%X This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia< 1 109/ml (odds ratio [OR] 0.33, 95% confidence interval [95% CI] 0.16–0.69, p = .003), active graft versus host disease (GvHD; OR 0.51, 95% CI 0.27–0.98, p = .04) and vaccination within the first year of transplant (OR 0.3, 95% CI 0.15–0.9, p = .04) associated with lower antibody detection whereas. In ASCT, non-Hodgkin's lymphoma (NHL; OR0.09, 95% CI 0.02–0.44, p = .003) and active corticosteroid therapy (OR 0.2, 95% CI 0.02–0.87, p = .03) were associated with lower detection rate. We report an encouraging rate of SARS-CoV-2-reactive antibodies detection in these severe immunocompromised patients. Lymphopenia, GvHD, the timing of vaccine, and NHL and corticosteroids therapy should be considered in allo-HSCT and ASCT, respectively, to identify candidates for SARS-CoV-2 antibodies monitoring.
%K Antibodies, Viral
%K COVID-19
%K COVID-19 Vaccines
%K Hematopoietic Stem Cell Transplantation
%~